Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data

Ocugen faces rising cash burn and heightened dilution risk as it advances late-stage gene-therapy programs, with pivotal data readouts and regulatory filings slated for 2026–2027 expected to drive meaningful share volatility. The company will likely need additional financing before potential approvals, increasing downside risk to equity holders from possible share issuance and short-term price swings.

Analysis

Ocugen faces rising cash burn and heightened dilution risk as it advances late-stage gene-therapy programs, with pivotal data readouts and regulatory filings slated for 2026–2027 expected to drive meaningful share volatility. The company will likely need additional financing before potential approvals, increasing downside risk to equity holders from possible share issuance and short-term price swings.